Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa cancer immunology treatment BI 770371
State on share capital and voting rights (FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.